Aerify3: A Potential New Treatment for Airway Inflammation in COPD

Trial Objectives

Treatments for chronic obstructive pulmonary disease (COPD) may still leave people experiencing wheezing, coughing, or shortness of breath. Researchers in the Aerify3 study are investigating a medication called itepekimab, which has shown some potential in earlier clinical trials to improve symptoms in those with COPD.

COPD symptoms can be worsened by inflammation in the lungs that makes it harder to breathe. Itepekimab has been shown to reduce inflammation in the body without suppressing the immune system. This trial is investigating changes in gene expression in those treated with this drug to evaluate how their lung inflammation has been reduced.

Participants will undergo two bronchoscopies within the first 12 weeks of the study, and biopsies will be taken to study gene expression during the procedures. They also will be monitored for changes of symptoms and receive blood tests to monitor
changes in the blood cells.